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Abstract: Hepatocellular carcinoma (HCC) represents a major and steadily 
increasing global health challenge as the most common primary liver malig-
nancy and leading cause of death in cirrhotic  patients. The only hope for cura-
tive treatment or significant increase in life expectancy is early  detection. Once 
patients have progressed towards end-stage HCC, effective treatment options 
are extremely limited on the background of a very high degree of heterogeneity 
in clinical presentation and  outcome. Experimental chronic liver injury and 
cancer have been used extensively to mimic the human  disease. In particular, 
mouse studies have advanced the field due to the ability to easily manipulate 
the mouse genome and transcriptome for mechanistic  evaluations. In addition, 
they offer the opportunity to screen new therapeutic strategies cost-effectively 
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and in quick high-throughput, large-scale  formats. The most commonly used 
mouse models in HCC research can be categorized as chemotoxic, diet-induced, 
and genetically engineered  models. It is important to note that no particular 
model mimics all features of a given HCC etiology or histological subtype, and 
each model poses advantages and disadvantages that need to be carefully 
 considered.
Keywords: cirrhosis; hepatocellular carcinoma; hydrodynamic tail vein injection; 
non-alcoholic fatty liver disease; non-alcoholic steatohepatitis.
INTRODUCTION
Liver cancer is the seventh most common cancer worldwide, and one of the 
deadliest, with a 5-year survival rate in the range of 5–30% (1). A recent assess-
ment by the Global Burden of Disease Cancer Collaboration revealed that 1 in 
38 men and 1 in 111 women will develop liver cancer at some point in their 
lives (2). In 2016, liver cancer contributed to approximately 10% of all cancer-
related deaths worldwide, ranking second in terms of the absolute number of 
years of life lost, only behind lung cancer (2). High morbidity and mortality 
rates underscore the need to develop platforms to identify diagnostic tools for 
better and earlier detection and more effective targeted therapies, in order to 
halt disease progression and improve survival of  patients. Therefore, appropri-
ate preclinical models of liver cancer, in particular hepatocellular carcinoma 
(HCC)—the most common type of liver cancer, representing approximately 
70% of all primary liver malignancies (3, 4)—are critical research tools that 
enable breakthroughs in the biology of hepatocarcinogenesis and testing of 
novel  therapies. Current therapy options for HCC are limited to surgical and 
non-surgical ablative therapies or liver transplantation; systemic approaches, 
such as treatments with multikinase inhibitors, only prolong the life expectancy 
of patients by 2–3 months (5).
Human hepatocarcinogenesis typically occurs secondary to chronic liver 
 diseases. These include the iron overload disorder hemochromatosis, viral hep-
atitis, alcoholic fatty liver disease (AFLD), and non-alcoholic fatty liver disease 
(NAFLD), all of which can promote steatosis, the build-up of excess fat in liver 
cells, and steatohepatitis, when the condition is accompanied by inflammatory 
and fibrogenic  components. Steatohepatitis causes cellular damage and oxida-
tive stress and instigates the release of pro-inflammatory and pro-fibrogenic 
signaling molecules, which (i) recruit immune cells to the site of injury, 
(ii)  induce hepatic stellate cell-mediated collagen deposition in the hepatic 
wound healing response, and (iii) activate liver progenitor cells, as part of a so-
called Ductular reaction, to replace lost tissue (6, 7). If injury is halted, matrix 
is resorbed and normal liver architecture is  restored. However, chronic patho-
logical insults can lead to excessive fibrosis, cirrhosis, and ultimately liver 
 cancer (Figure 1) (7).
Micehave become the pillar for biomolecular discovery in human disease due 
to numerous advantages over other model organisms (8, 9). An ever-growing list 
of mouse models has been developed to study different aspects of chronic liver 
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disease and progression to  HCC. However, appropriate recapitulation of human 
pathological features has been  challenging. Furthermore, when analyzed in detail, 
distinct models have been shown to induce remarkably different pathological 
 patterns (10). This chapter describes some commonly used as well as the most 
recently developed mouse models of  HCC. Table 1 indicates the timeframe for 
HCC development and highlights some of the most prominent features and 
 characteristics of each model discussed in this chapter (Table 1).
A variety of strategies can be used to generate HCC in  mice. These involve 
administration of toxic agents, genetic modifications such as expression of onco-
genes or disruption of tumor suppressor genes, cancer-promoting diets, and 
xenograft implantation  models. Often, multiple strategies are combined in order 
to achieve clinically relevant disease progression to mimic human  HCC. Thus, it 
is important to choose the most appropriate model and time point to best answer 
an underlying research  question. Importantly, it may be necessary to validate 
novel therapeutic targets across multiple models before they can be considered for 
translation into clinical  trials.
CHEMOTOXIC MODELS
Several hepatotoxins have been used to induce HCC in  mice. These chemicals 
either cause DNA damage directly and, therefore, produce cancer-promoting 
mutations, or act indirectly by facilitating clonal expansion of transformed 
cells  (11). Timing and reproducibility of tumor development can vary signifi-
cantly between different compounds and, interestingly, between studies from 
Figure 1 Progressive stages of liver disease to hepatocellular carcinoma development. Chronic 
liver diseases that predispose to hepatocellular carcinoma (HCC) are generally characterized 
by steatosis and hepatocellular damage or death, followed by inflammation and fibrosis. 
These are initial and potentially reversible wound healing when the disease stimulus is 
withdrawn. However, if the injury is persistent, liver disease may progress to end-stage 
complications such as cirrhosis and HCC.
Healthy Steatosis
Inflammation
Fibrosis Cirrhosis HCC
 CHRONIC LIVER DISEASE
(such as viral hepatitis, alcoholic and
non-alcoholic fatty liver disease, haemochromatosis)  
Stages of liver damage and progression to HCC
Potentially reversible if injury is halted or with treatment
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TABLE 1 Commonly used mouse models of hepatocellular 
carcinoma classified as chemotoxic, diet-based, 
and genetic
Model
HCC development 
(time) Features References
Chemotoxic
DEN Males >80%, 
females 10–30% 
incidence at 
9  months. 
Neutrophil infiltration, bile duct 
proliferation, centrilobular hemorrhagic 
necrosis, bridging  necrosis. No fibrosis 
or  cirrhosis.
(15–18, 21–27)
CCl4 1–2 years for most 
mice  strains. As 
early as 15 weeks 
in A/J mice
Hepatocyte necrosis, steatosis, Kupffer cell 
activation, immune cell  infiltration. 
Fibrosis precedes  HCC.
(42–52)
TAA 6–12 months Mild steatosis, centrilobular necrosis, 
severe  inflammation. Steady progressive 
worsening of inflammatory, fibrogenic 
and progenitor cell  responses. Strong 
centrally-driven fibrotic component, 
progressing to cirrhosis prior to  HCC.
(10, 58–61, 
63–68, 
71–74)
DEN+CCl4 100% incidence at 
5 months
Similar to CCl4 alone but with shortened 
HCC latency and increased presence of 
progenitor  cells.
(54, 55)
DEN+TAA+HFD 100% incidence at 
6 months
Reliable progression to HCC with short 
 latency. Includes steatosis, inflammatory 
and fibrogenic  features.
(75)
Diet
CDE 75% incidence at 
14 months
Periportal injury, severe steatosis at early 
 stages. Mild to moderate fibrosis, strong 
liver progenitor cell  component. 
(10, 92, 93)
ALIOS 60% incidence at 
1 year
Severe steatosis, hepatic necrosis and 
 inflammation. Ballooning hepatocytes 
and Mallory hyaline at 16  weeks. Mild 
periportal to bridging fibrosis, later liver 
progenitor cell  involvement.
(97, 98)
DIAMOND 89% incidence at 
1 year (can be 
accelerated to 
6 months by 
combination 
with CCl4).
Pronounced hepatocyte ballooning and 
progressive fibrosis at 6  months. 
Strong histologic and transcriptomic 
similarities with human NASH 
and  HCC.
(99–101)
Table continued on following page
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TABLE 1 Commonly used mouse models of hepatocellular 
carcinoma classified as chemotoxic, diet-based, 
and genetic (Continued)
Model
HCC development 
(time) Features References
MUP-uPA+HFD 78.6% incidence at 
32–40 weeks
Several hallmarks of human NASH 
(activation of hepatic stellate 
cells, bridging fibrosis, immune 
cell infiltration, and ballooning 
hepatocytes), Highlights the role of ER 
stress in HCC  development.
(102, 103)
Genetic
c-Myc Incidence of 40% at 
45 weeks, 60% 
at 55 weeks, and 
80% at 65 weeks
Mild to severe hepatic dysplasia at 2–3 
months of  age. First carcinogenic 
lesions at about 1 year of  age. Can 
be accelerated by co-expression of 
TGF-a and prevented by  HGF. HCC 
development drastically accelerated by 
co-treatment with CCl4.
(109–113)
E2F1 Incidence of 33% at 
1 year
Hepatic dysplasia at 2 months and 
adenomas at 6  months. HCC 
development accelerated by c-Myc 
co-expression.
(115, 116)
Active β-catenin 
+H-rasG12V
100% incidence 
within 2 months 
of genetic 
manipulation
Active b-catenin alone does not progress 
to  HCC. Combination with H-rasG12V 
induces rapid HCC  development. 
Dysplastic hepatocytes surrounded by 
immune infiltration in the first 4 weeks 
and multifocal nodules by 5  weeks.
(122, 123)
Apc KO 67% incidence at 
8–9 months
Dose of adenoviral injections is key 
(0.5 × 109  pfu). High doses increase 
mortality  risk. Trabecular and well-
differentiated  HCCs.
(124, 125)
Trp53 KO 14–20 months Majority of tumors display bipotential 
cell phenotypes (co-expression of 
hepatocyte and biliary  markers).
(127, 129)
PTEN KO Incidence of 47% 
at 44 weeks and 
66% at 74–78 
weeks
Hepatomegaly and steatosis at 10 
 weeks. Features of NASH (hepatic 
inflammation and fibrosis) at 40  weeks.
(132, 133)
Active β-catenin, β-catenin gene Ctnnb1 lacking exon 3; ALIOS, American lifestyle-induced obesity syndrome; Apc, 
adenomatous polyposis coli; CCl4, carbon tetrachloride; CDE, choline-deficient and ethionine-supplemented diet; c-Myc, 
Myc proto-oncogene; DEN, diethylnitrosamine; DIAMOND, diet-induced animal model of non-alcoholic fatty liver disease; 
E2F1, E2F transcription factor 1; HFD, high-fat-diet; H-rasG12V, substitution of glycine with valine at position 12 of human 
RAS; MUP-uPA, major urinary protein-urokinase-type plasminogen activator transgenic mice; PTEN KO, liver-specific 
knockout of phosphatase and tensin homolog; TAA, thioacetamide; Trp53 KO, liver-specific knockout of the mouse p53 
 ortholog.
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different research  groups. The latter possibly reflects differences in the murine gut 
microbiota, which are known to play key roles in tumor growth, as recently dem-
onstrated in pancreatic and colon cancer as well as melanoma (12). Hepatotoxins 
that are generally regarded as appropriate tumor inducers mostly recapitulate the 
multistep progression stages of human HCC involving injury, steatosis, inflamma-
tion, fibrosis, and  carcinogenesis. However, the degree and level of interplay of 
these histological changes often  varies. The most commonly used hepatotoxins to 
study HCC in mice are discussed  below.
Diethylnitrosamine (DEN)
DEN, also known as N-nitrosodiethylamine, is probably the most commonly used 
chemical to induce liver cancer in mice and is either administered orally or 
through peritoneal  injection. DEN is bioactivated in centrilobular hepatocytes in 
a cytochrome P450-dependent manner and produces metabolic sub-products 
that have DNA alkylating properties, ultimately leading to mutagenesis (13). 
Tumor incidence is reduced in CYP2 E1-deficient compared to wild-type mice, 
suggesting that it may be one of the key CYP enzymes that catalyzes DEN 
 bioactivation (13). DEN administration also induces reactive oxygen species 
(ROS)  formation and oxidative stress, which constitutes an additional mechanism 
by which it promotes hepatocarcinogenesis (14).
A single intraperitoneal dose of 5 mg/kg of DEN to weaning, 15-days-old male 
mice is sufficient to induce hepatocarcinogenesis in approximately 80% of all 
animals 9 months after induction (15). However, long-term administration or 
higher doses of DEN can reach an incidence of 100% in shorter timeframes 
(15–18). While DEN reliably induces HCC, dose, timing of administration, 
 gender, age, and strain impact the severity and timing of tumor appearance (19). 
High cellular proliferation is known to enhance mutagenesis by chemical 
 carcinogens both in vitro and in vivo (20). Thus, in most cases, juvenile mice are 
used, which display actively proliferating hepatocytes at this stage of their devel-
opment. DEN treatment results in the expansion of cells with oncogenic muta-
tions, leading to dysplastic lesions that eventually give rise to carcinomas (19).
Vesselinovitch and Mihailovich conducted an extensive dose–time response 
kinetics study of DEN-induced hepatic carcinogenesis, which included evalua-
tion of early alterations such as basophilic foci and nodules, as well as late trans-
formation to adenomas and hepatocellular carcinoma lesions (21). Briefly, HCC 
developed more reliably when DEN was administrated to younger mice (15-days 
old) in a dose-dependent manner, ranging from as little as 0.625 up to 5 mg/kg 
of body weight, whereas treatment of more mature mice (42-days old) with doses 
up to 50 mg/kg failed to induce predictable carcinogenesis within the same obser-
vational period of up to 110 weeks (21).
Another factor influencing the carcinogenicity of DEN is the  gender. The 
incidence for DEN-induced liver cancer can reach 100% for male mice, but is 
only approximately 10–30% in females, indicating a gender-specific differential 
response (22–27). Nakatani et  al. studied the influence of hormonal factors 
and demonstrated that ovariectomy or testosterone supplementation increased 
the occurrence of liver tumors in females treated with  DEN. Furthermore, 
male  castration paralleled by estrogen administration resulted in a reduced 
tumor incidence of 26%, similar to the prevalence observed in females (28). 
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These findings in experimental liver carcinogenesis are consistent with the 
observation that men are three to five times more likely to develop HCC than 
women (29). The precise molecular mechanisms underlying gender imbalance 
are not completely understood, but have recently been demonstrated to involve 
estrogen-dependent  interleukin (IL)-6 inhibition in females, and direct down-
stream effects in nuclear factor kappa B (NF-κB) and signal transducer and 
activator of transcription 3 (STAT3) signaling, two key transcription factors in 
HCC development (24, 30).
The sequence of hepatic alterations in DEN-treated mice is highly similar to 
human chronic liver disease to HCC  progression. During the course of their life, 
mice subjected to DEN develop histological alterations that include neutrophil 
infiltration, bile duct proliferation, centrilobular hemorrhagic necrosis, and bridg-
ing necrosis, all of which are observed in human HCC (31). However, the most 
common histopathological features of human HCC, fibrosis, and cirrhosis (32) 
are not observed with DEN administration alone (33). Indeed, 80–85% of all 
cases of HCC occur in cirrhotic patients, and only about 10% of HCC cases are 
reported in the absence of any chronic liver disease (34). Thus, models that 
include fibrogenesis are most relevant to a better understanding of the pathogen-
esis of human  disease. The combination of DEN with fibrotic compounds such as 
carbon tetrachloride (CCl4) and thioacetamide (TAA) has been demonstrated to 
better model this particular feature of HCC (35).
Carbon tetrachloride (CCl4)
CCl4 was widely used as a fumigant, cleaning product, and in fire extinguishers 
until it was phased out due to safety concerns and banned worldwide in 1996, 
under the “Montreal Protocol on Substances that Deplete the Ozone  Layer.” CCl4 
is a hepatotoxin known to induce liver damage, infiltration of inflammatory cells, 
and fibrosis (36). Similar to DEN, hepatotoxicity involves metabolism through 
cytochrome P450 and generation of toxic metabolic sub-products in hepatocytes 
(37, 38). One of them, trichloromethyl radical (CCl3*), is a highly reactive inter-
mediary that can damage nucleic acids, proteins, and lipids, leading to impair-
ments in diverse cellular processes (39). The main mechanism for CCl4-induced 
hepatic toxicity involves exacerbated lipid peroxidation, which leads to plasma 
membrane damage and secondary accumulation of lipoproteins and lipid droplets 
in hepatocytes (40, 41). Thus, one advantage of the CCl4 model is that it includes 
hepatic steatosis in its  pathogenesis. Additionally, CCl4 promotes activation of 
Kupffer cells, and this has been demonstrated to be necessary for its fibrogenic 
effect (42). Pro-inflammatory signaling mediated by Kupffer cells attracts further 
immune cell recruitment and infiltration, which contributes to the tissue damage 
elicited by CCl4 administration (43). A single dose of CCl4 leads to centrilobular 
liver necrosis, followed by tissue repair and regeneration (44). Thus, in contrast to 
DEN, CCl4 must be administrated chronically and/or repeatedly in order to lead 
to cycles of injury, inflammation, fibrosis, and cirrhosis, and it eventually gives 
rise to HCC (11).
CCl4 is most often provided to mice as a 2–4 mL/kg 50% solution in mineral 
or vegetal oil, either by gavage or intraperitoneally (45–47). However, a signifi-
cant variation in dosage can be found in the  literature. Inhalation exposure has 
also been utilized, although this route is much less common (48). The frequency 
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of doses also varies in different protocols, but generally consists of weekly, 
biweekly, or three times a week  administrations. While the pathology induced 
by CCl4 has a prominent fibrogenic component (49, 50) and A/J male mice were 
shown to present 100% incidence of HCC following a protocol of only 17-weeks 
of CCl4 administration (49), the evolution to HCC generally only occurs after 
long-term exposures of 1–2 years for most mouse strains (11, 51, 52). Therefore, 
CCl4 is often combined with other tumor-promoting agents such as alcohol, 
DEN, and others, which allow for a more timely induction of hepatic carcino-
genesis, while maintaining the inflammatory and fibrogenic components that are 
akin to human HCC (53). For example, a single dose of DEN at 2 weeks of age, 
followed by biweekly administrations of CCl4 led to a two fold increase in carci-
nogenesis at 5 months of age (54, 55). Interestingly, this was associated with 
significant increase in the expression of progenitor cell markers in the non- 
cancerous parenchyma, suggesting the role of fibrosis in promoting cellular 
alterations that lead to  carcinogenesis. The presence of cells expressing progeni-
tor features has been associated with a more aggressive tumor phenotype and 
poorer outcomes in human studies (56, 57). However, the exact role of progeni-
tor cells in the development of HCC is largely unknown and is a subject of 
intense research in the field (7).
Thioacetamide (TAA)
TAA has mostly been used to induce fibrosis, cirrhosis, and liver cancer, including 
cholangiocarcinoma in rats, but studies increasingly emerge on hepatic TAA 
 toxicity in mice (10., 58–61). TAA is an organosulfur compound that undergoes a 
 two-step bioactivation through the flavin-adenine dinucleotide-containing mono-
oxygenases or cytochrome P450 via TAA sulfoxide (TASO or sulfine) to thioacet-
amide sulfdioxide (TASO2 or  sulfene). TASO2 is a highly reactive metabolite, 
which causes significant fat deposition, necrosis, and inflammatory cell aggregates 
in centrilobular areas, where TAA is metabolized (10, 62). The mechanisms of 
toxicity are believed to be secondary to its oxidant properties, including lipid per-
oxidation and production of ROS, dampening antioxidant defenses and exacerbat-
ing hepatic oxidative stress (62). In mice, it is usually administered by the addition 
of drinking water at 300 to 600 mg/L, allowing for a simple model to induce 
 carcinogenesis without the need for regular injections (10, 60, 63). However, it can 
also be administered intraperitoneally two to five times a week (63–65).
A detailed 6-week time course analysis by Köhn-Gaone and colleagues 
 compared the molecular and cellular injury dynamics of TAA-induced chronic 
liver injury to feeding of a choline-deficient and ethionine-supplemented 
(CDE) diet in mice (10). While the CDE diet induced periportal injury, steato-
sis, and  fibrosis with a peak of all measured injury parameters in the first 
2 weeks,  followed by slow normalization of liver histology and function, TAA 
supplementation led to progressively worsening inflammatory, fibrogenic, and 
liver progenitor cell  responses. Various studies have reported portal, portal–
portal, or portal–central bridging in the TAA model (63, 66–68). However, the 
 comprehensive time course analysis in C57BL/6 mice revealed that fibrosis is 
centrally driven in TAA liver injury and progresses to cirrhosis within only 
6  weeks of treatment (10). Long-term treatment with TAA alone has been 
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demonstrated to induce HCC within 14–16 weeks in rats (69, 70). Murine 
studies are much rarer in the literature and describe HCC development after 
26 weeks to 12 months of TAA treatment (71–74). Figure 2 illustrates tumor 
histology and characteristics of TAA-induced HCC development compared to 
CDE-mediated HCC development in mice after 7 months of  treatment.
Often, TAA has been used in combination with other methods to induce hepa-
tocarcinogenesis in a shorter  timeframe. For instance, combination of a single dose 
of DEN at 14 days, accompanied by 300 mg/L of TAA in the drinking water, along 
with high-fat-diet (HFD) feeding from 4 weeks of age, elicited histological features 
of inflammation, steatosis, and fibrosis that were significantly exacerbated as early 
as 12 weeks of treatment, and 100% of animals progressed to liver tumors by 
24 weeks (75). Such combinatory strategies not only recapitulate different features 
of human HCC but may also significantly reduce the time for tumor development 
and have therefore become quite popular in liver cancer research (76).
DIET-INDUCED MODELS
Recent advances in antiviral therapies, which can result in permanent suppression 
of hepatitis B virus (HBV) and eradication of HCV, are significantly reducing the 
incidence of HCC from viral etiology (77). Furthermore, the second and most 
prevalent risk factor for HCC, alcoholic steatosis, is relatively stable over time 
(78). This can be attributed to observations pointing to steady or decreasing trend 
of alcohol consumption per capita in most countries over the past decades (79). 
Therefore, NAFLD and its advanced form, non-alcoholic steatohepatitis (NASH), 
are responsible for the current and future increases in chronic liver disease and 
HCC incidence worldwide (80). NAFLD is the hepatic manifestation of the meta-
bolic syndrome and is estimated to affect an astonishing 24% of the world popula-
tion (81). NAFLD is generally accompanied by obesity, insulin resistance, and 
 dyslipidemia. Thus, diet-induced models that manifest those metabolic altera-
tions are well suited to represent human NAFLD-driven  HCC. Noteworthy, only 
a small fraction of patients with NAFLD progresses to HCC (82). The network of 
factors that predict NAFLD progression to NASH and carcinogenesis are poorly 
understood, hence the importance of appropriate pre-clinical models to further 
our knowledge in this particular setting (83, 84).
Several diet-induced mouse models exist that induce HCC; however, not all 
models replicate all the associated metabolic dysfunctions that are characteristic 
of human  NAFLD. Feeding rodents a diet deficient in choline (CD), for instance, 
is known to induce hepatic steatosis and progression to HCC (85). This has first 
been observed in rats (86, 87) and confirmed in a number of mouse strains (88). 
Mechanistically, choline deficiency leads to defects in phospholipid synthesis, 
lipoprotein secretion, oxidative damage, endoplasmic reticulum (ER) stress, and 
cell death (85). Diets that combine choline with methionine deficiency (MCD) 
induce even more severe pathology, characterized by steatohepatitis within 1–2 
weeks and fibrosis by 8–10 weeks of feeding (89, 90). However, both CD and 
MCD are not accompanied by other physiological hallmarks of the metabolic 
syndrome, namely dyslipidemia, glucose intolerance, and insulin resistance 
(91). Furthermore, these diets promote severe body weight loss and morbidity, 
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Figure 2 Histology and cellular characterization of CDE- and TAA-induced tumors. (A) Gross 
liver morphology assessment of C57BL/6J mice treated with CDE or TAA for 7 months 
demonstrates the development of advanced tumors. Hematoxylin and eosin (H&E) stains 
reveal the presence of a great variety of neoplastic changes and nodules. TAA-induced 
tumors comprise large polygonal cells with abundant eosinophilic cytoplasm and atypical 
stripped nuclei as well as moderate basophilic cell infiltrates. Similar characteristics are 
identified in CDE-induced tumors, although with weaker eosinophilic cytoplasm and 
enriched small basophilic cells. An altered stromal network of collagen III-composing fibers 
demonstrates the characteristic thickening of hepatic cell plates and diffuse reticulin 
structures within tumors. Reticulin crowding at the interface of tumorous and non-tumorous 
tissue indicates invasive tumor growth into the surrounding tissue. (B) Immunohistochemical 
staining of both CDE- and TAA-induced tumors with the biliary and liver progenitor cell 
markers cytokeratin 19 (CK19) and CK7 and the hepatocellular carcinoma (HCC) marker 
carbamamoyl phosphate synthetase I (CPS1) identifies the tumors as HCC with biliary and 
progenitor proliferation almost exclusively in extra-tumoral tissue. (C) Fluorescent labeling 
of the cellular components of the injury and regeneration niche, which hosts panCK+ biliary 
and progenitor cells (green), alpha-smooth muscle actin (aSMA)+ hepatic stellate cells (red) 
and CD45+ inflammatory cells (white), illustrates the cells’ close spatial relationship and 
potential for cellular cross-talk in the tumor-surrounding tissue of CDE and TAA mice. NT, 
non-tumor; T, tumor.
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and thus, they are generally not suitable for long-term experiments leading up to 
 HCC. In order to significantly reduce the time to carcinogenesis, ethionine, a 
non-proteinogenic cytotoxic methionine analogue, can be added to the CD diet 
(CDE) and induce severe hepatic inflammation with a strong proliferation of 
liver progenitor cells and activation of fibrosis-driving hepatic stellate cells in as 
early as 2 weeks of feeding (92). Long-term CDE feeding of C57Bl/6 mice 
induced HCC in 75% of animals, whereby tumor development was significantly 
inhibited following treatment with the multi-tyrosine kinase inhibitor imatinib 
mesylate (93). Features of CDE-induced HCC after 7 months of treatment are 
demonstrated in Figure 2 in comparison with tumors provoked by TAA 
 administration.
The HFD model involves feeding animals ad libitum diets containing a total of 
45% to75% calories intake derived from fats (94). Several formulations exist in 
which the types and percentages of fats vary significantly (95). In this model, 
hepatic steatosis, characterized by increased liver triglyceride accumulation and 
fatty acid synthesis, is accompanied by other features of the metabolic syndrome 
such as obesity, glucose intolerance, and insulin resistance (96). It is a very reliable 
model to induce simple hepatic steatosis; however, in most mouse strains, no 
additional liver damage and inflammation, neither development to HCC, are 
observed (83).
To produce a model that more closely resembles the human disease, Tetri et  al. 
developed a formulation containing nutrients commonly found in fast foods and 
kept mice under conditions designed to encourage sedentary behavior, the so-
called American Lifestyle-Induced Obesity Syndrome (ALIOS) model (97). The 
formulation included trans-fats and high-fructose corn syrup, in addition to 
removal of cage racks to promote low energy  expenditure. After 16 weeks under 
this regime, mice developed severe hepatic steatosis, associated with necrosis and 
 inflammation. Histological features of human NASH such as ballooning hepato-
cytes and Mallory hyaline were also  described. Fibrogenesis was not detected 
histologically; however, procollagen mRNA expression was found to be upregu-
lated, suggesting that fibrosis might develop at time points later than 16 weeks 
(97). Consistent with this hypothesis, a separate study used 12-month exposure 
to the ALIOS protocol and revealed fibrosis with severity ranging from mild peri-
portal to bridging fibrosis (98). These observations were accompanied by sub-
stantial activation of the liver progenitor cell niche, which was evidenced through 
increased numbers of cells positive for pan-cytokeratin (panCK) and sex- 
determining region Y-box 9 (Sox9) throughout the  parenchyma. HCC was 
observed in 60% of all ALIOS mice at 12 months (98). These studies demonstrate 
that diet and lifestyle interventions are sufficient for the induction of NASH and 
hepatocarcinogenesis in  mice. Future studies are necessary to assess the level of 
similarities between the genetics and transcriptomics of carcinogenesis observed 
in ALIOS mice compared to human  HCC.
Another western diet model, comprised of high cholesterol, high saturated fat, 
and high fructose, has been shown to promote NASH, which was characterized by 
pronounced hepatocyte ballooning and progressive fibrosis after 6 months of 
feeding (99). No HCC was observed at 6 months, but it resulted in 89% incidence 
of spontaneous HCC after 12 months of feeding to a stable isogenic cross between 
C57BL/6J and S129 mice (100). Interestingly, this model, named Diet-Induced 
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Animal Model Of Non-alcoholic fatty liver Disease (DIAMOND), presented 
remarkable histologic and transcriptomic similarities with human NASH and 
 HCC. Tsuchida et  al. recently demonstrated that the same diet, combined with 
low weekly doses of CCl4, can develop rapid progression to stage 3 fibrosis and 
HCC within 12 and 24 weeks,  respectively. The pathology closely mimicked his-
tological, immunological, and transcriptomic features of human NASH, thus rep-
resenting a rapid induction model suitable to study hepatocarcinogenesis in a 
clinically relevant setting (101).
Most recently, another diet-induced model of NASH-driven HCC was estab-
lished through genetically induced predisposition to  HCC. Feeding of a HFD to 
major urinary protein (MUP)-urokinase-type plasminogen activator (uPA) trans-
genic mice, which overexpress uPA specifically in hepatocytes, induced liver dis-
ease that recapitulated several hallmarks of human NASH and reliable progression 
to HCC (102). In comparison with HFD-fed control wild-type animals, MUP-uPA 
mice displayed increased activation of hepatic stellate cells as well as upregulation 
of collagen and other fibrogenic  markers. Immune cell infiltration, bridging fibro-
sis, and ballooning hepatocytes were all present in MUP-uPA mice at 24 weeks 
after diet  initiation. Hepatocarcinogenesis was observed at 32–40 weeks of HFD 
feeding in about 78.6% of these  animals. The mechanism of disease progression 
involved excessive ER stress, induced by hepatocyte overexpression of uPA and 
exacerbated by HFD, as well as tumor necrosis factor (TNF)-dependent inflam-
mation (102). This model was later used to demonstrate the key role of caspase-2, 
downstream of TNF and ER stress, in mediating the activation of sterol regulatory 
element-binding proteins (SREBP), recognized to participate in NASH develop-
ment (103).
GENETICALLY ENGINEERED MODELS
Human HCC is known to have a very high level of inter- and intra-tumor genetic 
heterogeneity (104). Illustrating this concept, a study by Schulze and colleagues 
employed exome sequencing analysis and identified mutations in 161 distinct 
putative driver genes in a cohort of only 243 hepatic tumors (105). In addition, a 
recent study published by the Cancer Genome Atlas Research Network investi-
gated 383 HCC cases by whole-exome sequencing and DNA copy number analy-
ses and assessed 196 HCC samples for their DNA methylation, RNA, miRNA, and 
proteomic  status. The comprehensive data set, coupled with robust statistical 
power by the large investigated cohort, enabled the identification of various 
molecular signatures, which may be therapeutically targeted in different HCC 
subgroups (106). The individual roles of many of the identified genes and path-
ways in hepatocarcinogenesis have been, and continue to be, determined using 
mouse  genetics. Such models are excellent tools to investigate the discrete effects 
of candidate oncogenes or tumor suppressor genes in  HCC. The number of genet-
ically engineered mouse models of HCC is very large and continuously  expanding. 
Moreover, comprehensive reviews describing available models have been pub-
lished elsewhere (107). The scope of this chapter is to present a few of the most 
commonly used and well-characterized genetic models in  detail.
Mouse Models of Hepatocellular Carcinoma 81
c-Myc
The transcription factor c-Myc controls numerous cellular processes, including 
cell cycle progression and  proliferation. Mutations that activate c-Myc are known 
to be highly associated with carcinogenesis in human HCC (108). Transgenic 
mice, overexpressing c-Myc specifically in the liver, develop hepatic tumors with 
a relatively long latency of approximately 12–15 months (109–111). Tumor inci-
dence is of about 40% at 45 weeks of age, 60% at 55 weeks, and 80% at 65 weeks 
(111). To limit oncogene expression to the hepatic tissue, the albumin promoter 
has most commonly been utilized due to its specificity to hepatocytes (11). When 
c-Myc was combined with transgene expression of growth factors such as trans-
forming growth factor alpha (TGF-α) and hepatocyte growth factor (HGF), oppos-
ing results were  obtained. Combination with TGF-α led to a significant acceleration 
of the neoplastic development, with tumors developing before 16 weeks of age 
(110). In contrast, HGF prevented malignant transformation when investigated in 
a similar setting (112). Interestingly, the kinetics of carcinogenesis induced by 
c-Myc can be drastically accelerated to under 40 days by co-treatment with the 
hepatotoxins CCl4 or 5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) (113). An 
elegant study by Shachaf and colleagues demonstrated that inactivation of the 
MYC oncogene resulted in tumor regression, accompanied by differentiation of 
the tumor cells into hepatocytes and  cholangiocytes. The tumors lay dormant 
until c-Myc was reactivated in cells the authors proposed to be cancer stem cell-
like cells (114).
The E2F transcription factor 1 (E2F1) has also been identified as frequently 
dysregulated and/or mutated and was demonstrated to induce HCC in mice upon 
hepatic transgenic overexpression (115, 116). E2F1 mice showed signs of hepatic 
alterations as early as 2 months of age, with most animals developing adenomas 
at 6  months. However, tumors progressed to HCC only in one-third of experi-
mental animals at 1 year of  age. Co-expression of E2F1 and c-Myc further acceler-
ated the appearance of focal lesions and severe dysplasia, leading to earlier 
development of HCC as compared to either of the oncogenes alone (117).
Wnt/β-catenin
Wnt/β-catenin signaling controls a plethora of cellular communication networks 
in embryonic development and demonstrates key roles in regulating stemness and 
cell differentiation in health and disease (118). Pathological alterations of this 
pathway are known for its involvement in many human cancers, including liver 
cancer (118, 119). Beta-catenin is one of the key effectors of Wnt signaling, and 
its gene CTNNB1 is the most frequently found mutated component of this path-
way in human HCC (120). Altered activity of β-catenin, as evidenced by mutation 
or nuclear translocation, was observed as an early event in hepatocarcinogenesis 
driven by distinct genetic models (121). Yet, constitutive activation of β-catenin 
through deletion of its regulatory domain was not sufficient to promote hepatic 
tumorigenesis by itself (122). When combined with oncogenic H-ras (H-rasG12V), 
however, β-catenin activation resulted in aggressive HCC development with 
100% incidence within 3–4 months following the genetic manipulation (123). 
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Interestingly, the most commonly used approach to induce hepatic β-catenin acti-
vation in mice has been the selective Cre-Lox disruption of its negative regulator, 
adenomatous polyposis coli  (Apc). This indirect approach for the stabilization of 
active β-catenin was shown to lead to spontaneous hepatocyte hyperplasia and 
67% incidence of HCC in the surviving animals following 8–9 months of model 
establishment (124). Tumors generated through this model have recently been 
shown to possess a unique metabolic signature, characterized by exacerbated fatty 
acid utilization (125), suggesting that inhibition of fatty acid oxidation could be a 
potential therapeutic approach for β-catenin-induced  HCC.
Liver-specific knockout models
Liver-specific knockout models of tumor suppressor genes have also been devel-
oped and utilized either alone or in combination with other insults to study liver 
 cancer. The TP53 gene that encodes for the tumor suppressor p53 is found 
mutated in most human cancers, including HCC (126). P53 knockout mice dis-
played a significantly increased hepatocyte proliferation rate and LPC-like cells in 
periportal liver regions (127). In addition, p53-/-LPCs isolated from these mice 
and injected subcutaneously into athymic nude mice generated tumors with a 
HCC morphology (128). In a separate study, the homozygous deletion of Trp53 
(the mouse ortholog), specifically in the liver, led to HCC formation after 
14 months of age (129). The authors also showed that p53 deletion gave raise to 
tumors with a bilineal phenotype and increased proliferation of liver progenitor 
 cells. These observations support a model in which loss of function of p53 may 
promote HCC through an increase in the proliferative capacity of progenitor  cells.
Another ubiquitously expressed tumor suppressor gene frequently found 
mutated or downregulated in human HCC is phosphatase and tensin homolog 
(PTEN) (130, 131). Its phosphatase activity inhibitsphosphatidylinositol-3- 
kinases (PI3K) and consequently suppresses downstream protein kinase B (PKB/
Akt) and mammalian target of rapamycin (mTOR) growth-promoting  signaling. 
Horie et  al. generated a liver-specific PTEN knockout model through the crossing 
of albumin promoter Cre mice with PTEN-floxed mice (132). The resulting 
 conditional PTEN knockout mice showed hepatomegaly and steatosis as early as 
10 weeks of  age. At 40 weeks, features of NASH including hepatic inflammation 
and fibrosis were  observed. This model also reliably progressed to tumorigenesis, 
although with a long  latency. The incidence of hepatic adenomas was 47% at 
44 weeks, and by 74–78 weeks, 66% of animals displayed HCC (132). The mech-
anism of carcinogenesis driven by PTEN disruption has later been  addressed. It 
involves hepatic injury-dependent expansion of epithelial cellular adhesion 
 molecule (EpCAM), alpha-fetoprotein (AFP), and cytokeratin 19 (CK-19) positive 
progenitor cells (133).
Hydrodynamic tail vein injection (HTVI) models
Traditionally, genetic modifications, such as gene knockouts, knockins, and trans-
gene overexpression, were introduced in the germline of parent mouse strains to 
produce whole body genetic alterations (134). This approach has been extensively 
used in HCC research; however, advances in genetic manipulation tools, such as 
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Cre-Lox recombination, have allowed for a much more precise spatial and 
 temporal control of candidate genes expression, and their utilization has become 
widespread (135). Notably, this kind of approach has been used to produce con-
ditional liver-specific genetic manipulations, overcoming the problem of embry-
onic lethal gene mutations as well as restricting phenotypes to the hepatic  tissue. 
Nonetheless, these are both expensive and time-consuming  strategies.
A simple and inexpensive alternative method to transfect and gene-edit 
 hepatocytes in vivo is represented by hydrodynamic tail vein injection (HTVI) of 
“naked” plasmid DNA (non-viral vector, not associated with protective proteins 
or lipids) directly into the liver of adult mice (136, 137). The technique consists 
of rapid injection of a large amount of plasmid DNA (about 50 μg in a volume of 
saline that signifies 10% of the body weight of the injected mouse) into the mouse 
lateral tail vein (138). HTVI results in transient heart dysfunction and fluid accu-
mulation in the inferior vena  cava. The enormous hydrodynamic pressure then 
forces the fluid into the liver in a retrograde movement, enlarges the liver, and 
pushes the plasmid DNA into hepatocytes via enlarged sinusoidal fenestrae and 
transient membrane pores (139), with transfection efficiencies ranging from 
around 10 to 40% of all hepatocytes (136, 140). While the liver is primarily tar-
geted, other organs including heart, kidney, lung, and spleen are also affected by 
HTVI; however, to only 0.1% of the levels achieved in the liver (138, 141). One 
caveat of HTVI is that the expression of transfected genes is transient, peaking 
within 24 h, but dropping dramatically thereafter (142). In order to circumvent 
this pitfall, HTVI has been combined with DNA recombination technologies such 
as Cre-Lox, sleeping beauty (SB) transposase, and CRISPR-Cas9, allowing for 
genomic  integration and continuous expression of genetic  modifications. HTVI 
has been used increasingly to study genetic factors influencing HCC biology, and 
a variety of HCC models have recently been developed using this  approach. 
Particularly, HTVI permits the assessment of more than one genetic alteration at 
the same time and therefore the investigation of the combinatory effects of target-
ing multiple pathways  simultaneously. A number of models created through HTVI 
are discussed below and are summarized in Figure 3.
The PI3K/AKT/mTOR pathway is central in the regulation of hepatocyte cell 
metabolism, growth, and proliferation (143). Upregulation of this pathway is fre-
quently observed in human HCC (144, 145) and is associated with poorer out-
comes (146). As described before, conditional liver knockout of PTEN, a negative 
regulator of this pathway, induces NASH-like liver disease and HCC in mice 
(132). HTVI was used to introduce a constitutively active form of AKT (myris-
toylated AKT) that induced HCC about 6 months post-injection (147). Wild-type 
mice were co-injected with SB transposase and active AKT vectors for somatic 
 integration. Disease progression resembled that of PTEN knockout mice, with 
increased lipogenesis and upregulation of genes involved in fatty acid synthesis 
(147). Importantly, the expression of transfected AKT was observed in relatively 
few cells, which were surrounded by non-transfected  hepatocytes. This is consid-
ered to be an advantage of HTVI, in that it better resembles human liver cancer, 
where only a limited number of foci are believed to give rise to HCC (140).
It was later reported that co-injection of AKT along with H-rasG12V signifi-
cantly increases the kinetics of liver tumor development, with 100% of injected 
animals presenting tumors within 4 weeks post-injection (148). Similar kinetics 
were observed when AKT was co-expressed with active β-catenin (149). 
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Interestingly, injection of H-rasG12V alone did not lead to HCC (148, 150). 
However, when expressed in p19 Arf knockout mice, H-rasG12Vinduced HCC in 
all mice within 6 weeks that otherwise did not develop with simple disruption of 
this positive regulator of p53 (150). In a similar way, H-rasG12V combined with a 
shRNA construct targeting p53 led to hepatocarcinogenesis within only 4 weeks 
(151). This study also demonstrated that oncogenic vectors can be combined 
with a SB transposase plasmid containing a firefly luciferase expression cassette, 
allowing for tumor growth to be monitored non-invasively over time through 
bioluminescence  imaging. Altogether, these results highlight the suitability of 
HTVI to create models that allow for the utilization of synergistic pathways in 
promoting HCC for rapid induction studies and proof-of-concept therapeutic 
 interventions.
Notably, the SB transposase system permits efficient genomic recombination of 
exogenous sequences; however, this approach is not specific in terms of the inte-
gration site (152). Recombination can potentially occur virtually anywhere in the 
Figure 3 Hydrodynamic tail vein injection models of hepatocellular  carcinoma. Plasmid DNA 
containing Cre-Lox, sleeping beauty transposase, and/or CRISPR-Cas9-based recombination 
sequences along with key oncogenes or tumor suppressor disruption sequences is injected 
into the lateral tail vein of young  mice. HCC develops with variable latency depending on the 
chosen genetic manipulation, as  indicated. Co-injection of luciferase expression cassette 
allows for in vivo monitoring of tumor growth by bioluminescence imaging  (BLI). HCC, 
hepatocellular carcinoma; KO,  knockout.
Fast (5-8s) injection into
lateral tail vein
(~50 µg plasmid DNA
in 2.5 ml saline)
Myristoylated AKT [HCC in 6 months (145)] 
Myristoylated AKT + H-rasG12V [HCC in 4 weeks (146)]
Myristoylated AKT + active β-catenin  [HCC in 4 weeks (147)]
H-rasG12V in p19ARF KO background [HCC in 6 weeks (148)]
H-rasG12V + Trp53 shRNA [HCC in 4 weeks (149)]
CRISPR-Cas9-mediated PTEN and Trp53 double KO
[HCC in 3 months (153)]
Co-injection of luciferase expression cassette 
allows for in vivo monitoring of tumour growth 
by bioluminescence imaging (BLI) (149) 
Variable latency depending on model
Cre-Lox, sleeping beauty
transposase, and/or
CRISPR-Cas9-based
plasmids
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genome, causing undesired disruption of off-target genes (153). The CRISPR-
Cas9 system, on the other hand, offers sequence-specific direct editing of DNA 
with only rare off-target mutations (154). In a proof-of-concept study, Xue et  al. 
utilized HTVI to generate CRISPR-Cas9-mediated knockouts of PTEN and p53, 
or combinations of the two, that phenocopied the traditional conditional liver 
knockouts of these genes (155). PTEN and/or p53 disruptions were shown to be 
present in 3 to 6% of all  hepatocytes. At 3 months post-injection, all animals with 
double disruptions developed liver tumors (155). The same approach was used to 
target β-catenin and simultaneously introduced a constitutively active version of 
 it. This notoriously less-efficient event, observed in only 0.5% of all hepatocytes, 
however, demonstrated that CRISPR-Cas9 can also be used to introduce gain-of-
function mutations, providing a highly specific and low off target method for the 
evaluation of novel gene roles in HCC development (155). Consequently, CRISPR-
Cas9 combined with HTVI has been increasingly utilized for HCC research in 
recent years (156–158).
CONCLUSION
HCC poses a global health challenge in terms of prevention, diagnosis, and 
 treatment. While epidemiological studies can provide information on associations 
between HCC and variables that influence its natural history, the progression of 
interventions into clinical practice requires demonstrated benefits and safety from 
carefully designed in vivo models such as the mouse models described  here. 
A large variety of experimental chronic liver injury and HCC models are currently 
available, each with particular characteristic features, mimicking diverse etiolo-
gies and disease progression  patterns. Selection of the most appropriate animal 
model allows for the study of disease context-specific as well as common carcino-
genic mechanisms and screening of novel therapeutic targets for clinical 
 translation. Until the tyrosine kinase inhibitor sorafenib was approved for unre-
sectable HCC in 2007, there was no FDA-approved therapies available for patients 
in advanced-stage chronic liver  disease. The improved understanding of the 
molecular mechanisms of HCC, primarily obtained from several of the animal 
models herein described, has culminated in the development of current targeted 
therapies, including sorafenib and  regorafenib. Several other agents have been 
tested, or are currently under clinical evaluation, and will hopefully contribute to 
improved HCC outcomes in the years to  come. There is no perfect animal model 
for human disease; however, mouse models are still invaluable and will continue 
to form the cornerstone of preclinical studies, designed to delineate interventions 
that are effective and safe in the  future.
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